Growth Will Suffer As J&J Reports Its First Quarter Results

There are two critical factors at play. First, J&J had pinned much of its hopes on its Hepatitis C drug Olysio for incremental future growth, but that hope has almost faded now due to competitive pressure and new entrants. The drug?s sales have dropped sharply. Second, the company?s biggest drug Remicade has gone off patent in Europe this year. We expect the upcoming quarter, and 2015 as a whole, to be notably different from last year in terms of revenue and EPS growth. J&J was cruising, but thi...